Clinical trials found substantial weight loss and improved cardiovascular outcomes associated with taking these medications
The impact of BMI on treatment response is well illustrated by the AQUILA study, which examined real-world outcomes in PsA patients treated with (65).In this cohort, obese individuals exhibited higher circulating levels of IL-17, supporting the concept that IL-17driven inflammation may be particularly prominent in this subgroup and may contribute to increased disease activity and reduced therapeutic responsiveness (66)
NOW products are being tested to determine such things as effectiveness for joint support, quality of life for cancer patients, cardiovascular support, and athletic endurance
Cochrane Database systematic Rev
Cytoprotective properties: Research has demonstrated that BPC may serve as a useful cytoprotective peptide therapy in heart disturbances, myocardial infarction, and heart failure (6)
The typical use level of Xantha Gum is below 1%, it is usually in the 0.1-0.5% range